[HTML][HTML] Esketamine in depression: putative biomarkers from clinical research
The discovery of racemic (R, S)-ketamine as a rapid-acting antidepressant and the
subsequent FDA approval of its (S)-enantiomer, esketamine, for treatment-resistant …
subsequent FDA approval of its (S)-enantiomer, esketamine, for treatment-resistant …
Ketamine and major ketamine metabolites function as allosteric modulators of opioid receptors
I Gomes, A Gupta, EB Margolis… - Molecular …, 2024 - molpharm.aspetjournals.org
Ketamine is a glutamate receptor antagonist that was developed over 50 years ago as an
anesthetic agent. At subanesthetic doses, ketamine and some metabolites are analgesics …
anesthetic agent. At subanesthetic doses, ketamine and some metabolites are analgesics …
11th Annual Pills and Thrills that Kill! Toxicology in Review, El Paso, Texas, April 3-4, 2024.
S Baeza - Texas Public Health Journal, 2024 - search.ebscohost.com
The article discusses the 11th Annual Pills and Thrills that Kill! Toxicology in Review
conference held in El Paso, Texas on April 3-4, 2024, focusing on new approaches to …
conference held in El Paso, Texas on April 3-4, 2024, focusing on new approaches to …